Osaka University

Hirokazu Kimura

Akira Kikuchi

Katsumi Fumoto

The purpose of the present invention is to provide an anti-CKAP4 monoclonal antibody that inhibits the binding of DKK1 and CKAP4 and exhibits an exceptional antitumor effect. Provided is an anti-CKAP4 monoclonal antibody that recognizes at least part of the 451-455 region, at least part of the 481-485 region, at least part of the 502-510 region, at least part of the 503-524 region and at least part of the 585-590 region, or at least part of the 585-592 region of the amino acid sequence (amino acid sequence of CKAP4) represented by SEQ ID NO:1 as an epitope, the anti-CKAP4 monoclonal antibody effectively inhibiting the binding of DKK1 and CKAP4, the activation of AKT of S2-CP8 cells, and the proliferative ability of S2-CP8 cells or the migratory ability of S2-CP8 cells, and exhibiting an exceptional antitumor effect. The ability to develop ELISA methods in which these anti-CKAP4 monoclonal antibodies are used furthermore makes it possible, for example, to measure the serum CKAP4 in pancreatic cancer patients, and therefore also contributes to the development of companion diagnostic agents.

Anti-CKAP4 monoclonal antibody

Disclosed is to identify a target molecule that is involved in Dkk1-induced hyperproliferation of tumor cells to provide a novel antitumor agent. Cytoskeleton-associated protein 4 (CKAP4) specifically regulates the hyperproliferation effects that are induced by dickkopf-related protein 1 (Dkk1), and proliferation of tumor cells can be suppressed by inhibiting expression or function of CKAP4 in the tumor cells.

Growing community of inventors

Suita, Japan

Hirokazu Kimura